Adriamycin and mitomycin C: possible synergistic cardiotoxicity. 1978

A U Buzdar, and S S Legha, and C K Tashima, and G N Hortobagyi, and H Y Yap, and A N Krutchik, and M A Luna, and G R Blumenschein

Ninety-one patients with advanced breast cancer failing adriamycin (ADR)-containing combination chemotherapy were treated with a combination of mitomycin C (MMC) and megestrol acetate. Congestive heart failure (CHF) occurred in 14 (15.3%) of 91 MMC-treated patients compared to three (3.4%) of 89 patients treated with similar ADR-containing combination chemotherapy without MMC (P = 0.01). The median time from the last dose of ADR to evidence of CHF was 8.5 months for the MMC group compared to 1.5 months for the other group. A significantly higher incidence of late onset of CHF implicates MMC as a possible cardiotoxic agent.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008937 Mitomycins A group of methylazirinopyrroloindolediones obtained from certain Streptomyces strains. They are very toxic antibiotics used as ANTINEOPLASTIC AGENTS in some solid tumors. PORFIROMYCIN and MITOMYCIN are the most useful members of the group.
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006333 Heart Failure A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION. Cardiac Failure,Heart Decompensation,Congestive Heart Failure,Heart Failure, Congestive,Heart Failure, Left-Sided,Heart Failure, Right-Sided,Left-Sided Heart Failure,Myocardial Failure,Right-Sided Heart Failure,Decompensation, Heart,Heart Failure, Left Sided,Heart Failure, Right Sided,Left Sided Heart Failure,Right Sided Heart Failure
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

A U Buzdar, and S S Legha, and C K Tashima, and G N Hortobagyi, and H Y Yap, and A N Krutchik, and M A Luna, and G R Blumenschein
September 1989, The Medical journal of Australia,
A U Buzdar, and S S Legha, and C K Tashima, and G N Hortobagyi, and H Y Yap, and A N Krutchik, and M A Luna, and G R Blumenschein
April 1981, Journal of molecular and cellular cardiology,
A U Buzdar, and S S Legha, and C K Tashima, and G N Hortobagyi, and H Y Yap, and A N Krutchik, and M A Luna, and G R Blumenschein
January 1985, Medical oncology and tumor pharmacotherapy,
A U Buzdar, and S S Legha, and C K Tashima, and G N Hortobagyi, and H Y Yap, and A N Krutchik, and M A Luna, and G R Blumenschein
February 1994, Indian journal of experimental biology,
A U Buzdar, and S S Legha, and C K Tashima, and G N Hortobagyi, and H Y Yap, and A N Krutchik, and M A Luna, and G R Blumenschein
April 1979, Cancer treatment reports,
A U Buzdar, and S S Legha, and C K Tashima, and G N Hortobagyi, and H Y Yap, and A N Krutchik, and M A Luna, and G R Blumenschein
January 1992, Cancer chemotherapy and pharmacology,
A U Buzdar, and S S Legha, and C K Tashima, and G N Hortobagyi, and H Y Yap, and A N Krutchik, and M A Luna, and G R Blumenschein
January 1974, Bollettino della Societa italiana di cardiologia,
A U Buzdar, and S S Legha, and C K Tashima, and G N Hortobagyi, and H Y Yap, and A N Krutchik, and M A Luna, and G R Blumenschein
January 1982, Giornale italiano di cardiologia,
A U Buzdar, and S S Legha, and C K Tashima, and G N Hortobagyi, and H Y Yap, and A N Krutchik, and M A Luna, and G R Blumenschein
May 1980, American heart journal,
A U Buzdar, and S S Legha, and C K Tashima, and G N Hortobagyi, and H Y Yap, and A N Krutchik, and M A Luna, and G R Blumenschein
January 1984, The American journal of cardiology,
Copied contents to your clipboard!